
Name of the Issue: ENTERO HEALTHCARE SOLUTIONS LIMITED

1 Type of Issue	Initial Public Offer
2 Issue Size (Rs. Mn)	16,000.00
- Fresh Issue Size (Rs. Millions)	10,000.00
- Offer for Sale Component (Rs. Millions)	6,000.00

*Source: Prospectus dated February 13, 2024

3 Grade of issue along with name of the rating agency

Name	NA
Grade	NA

4 Subscription Level (Number of times) 1.32*

* Figure is prior to rejections

Source: Basis of allotment ad dated February 15, 2024

5 QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges

Particulars	%age
(i) On Allotment **	24.95%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (March 31, 2024) [†]	25.58%
(iii) at the end of 1st FY (March 31, 2024) [^]	25.58%
(iv) at the end of 2nd FY (March 31, 2025)*	Not Available
(v) at the end of 3rd FY (March 31, 2026)*	Not Available

**Basis of Allotment

[†]Holding of institutions category as disclosed to Stock Exchanges

* QIB Holding not disclosed as reporting for relevant period has not been completed.

6 Financials of the issuer

Parameters	<i>(Rs. Million)</i>		
	1st FY (March 31, 2024)	2nd FY (March 31, 2025)*	3rd FY (March 31, 2026)*
Income from operations	3,182	Not Available	Not Available
Net Profit for the period	384	Not Available	Not Available
Paid-up equity share capital	435	Not Available	Not Available
Reserves excluding revaluation reserves	15,829	Not Available	Not Available

* Financials not available as reporting for the relevant years has not been completed.

7 Trading Status

The equity shares of Entero Healthcare Solutions Limited were listed on BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") in February 2024
The equity shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2024)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2025)*	Not Available
(iii) at the end of 3rd FY (March 31, 2026)*	Not Available

* Trading status not disclosed as the relevant fiscal year has not completed.
Source: Stock exchange data.

8 Change in Directors of Issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2024)#	None	None
(ii) at the end of 2nd FY (March 31, 2025)*	Not Available	Not Available
(iii) at the end of 3rd FY (March 31, 2026)*	Not Available	Not Available

* Changes in Directors of Issuer not updated as the reporting for the relevant financial years has not been completed

Updated till May 31, 2024

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds

(i) As disclosed in the offer document

(Rs. In Millions)

Particulars	Estimated utilisation from Net Proceeds	Estimated schedule of deployment of Net		
		2024	2025	2026
		(Rs. In millions)		
Repayment or prepayment of certain borrowings, in full or part availed by our Company	1425.00	1425.00	0.00	0.00
Funding of long-term working capital requirements of the Company and its Subsidiaries during Fiscals 2025 and 2026	4800.00	1500.00	2500.00	800.00
Pursuing inorganic growth initiatives through acquisitions*	2370.00	600.00	1770.00	-
General corporate purposes*	917.00	93.00	480.00	344.00
Total	9512.00	3618.00	4750.00	1144.00

*Source: Prospectus

*The amount to be utilised for general corporate purposes and inorganic growth initiatives does not individually exceed 25% of the Gross Proceeds respectively and does not exceed 35% collectively of the Gross Proceeds from the Fresh Issue, in accordance with Regulation 7(3) of the SEBI ICDR Regulations.

(ii) Actual utilization

(Rs. In Millions)

Particulars	Amount proposed to be funded from Net Proceeds	Actual Utilisation of Net Proceeds in Fiscal 2024 [†]	Actual Utilisation of Net Proceeds in Fiscal 2025	Actual Utilisation of Net Proceeds in Fiscal 2026
Repayment or prepayment of certain borrowings, in full or part availed by our Company	1425.00	1,425.00	NA	NA
Funding of long-term working capital requirements of the Company and its Subsidiaries during Fiscals 2025 and 2026	4800.00	1579.50	NA	NA
Pursuing inorganic growth initiatives through acquisitions*	2370.00	-	NA	NA
General corporate purposes*	917.00	102.70	NA	NA
Total	9512.00	3107.20		

[†]Actual Utilization not disclosed as reporting for the relevant fiscal year has not been completed.

Source - As per monitoring agency report dated May 15, 2024

(iii) Reasons for deviation, if any

Not applicable

11 Comments of monitoring agency, if applicable

(i) Comments on use of funds

(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document*

(iii) Any other reservations expressed by the monitoring agency about the end use of funds

**Source - As per monitoring agency report dated May 15, 2024*

NA

Revision in GCP is on account of actual offer expenditure being lower than estimated by INR 0.13 Crs.

NA

12 Pricing Data

Designated Stock Exchange	BSE
Issue Price (Rs.)	1258.00
Listing Date	16-Feb-24

Price parameters	At close of listing day (February 16, 2024)	Close of 30th calendar day from listing day (March 16, 2024) ⁽¹⁾	Close of 90th calendar day from listing day (May 15, 2024) ⁽²⁾	As at the end of the 1st FY after the listing of the issue (31st March, 2024) ⁽³⁾⁽⁴⁾		
				Closing price	High (During the FY)	Low (During the FY)
Market Price on Designated Stock Exchange ⁽⁵⁾	1,258.00	1,010.85	1,008.45	1,003.15	1,258.00	974.45
S & P BSE SENSEX ⁽⁶⁾	72,426.64	72,643.43	72,987.0	73,651.4	74,190.3	73,120.3
Sectoral Index ⁽⁶⁾	NA	NA	NA	NA	NA	NA

Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March, 2025) ⁽³⁾⁽⁴⁾			As at the end of the 3rd FY after the listing of the issue (31st March, 2026) ⁽³⁾⁽⁴⁾		
	Closing price	High	Low	Closing price	High	Low
Market Price on Designated Stock Exchange ⁽⁵⁾	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
S & P BSE SENSEX ⁽⁶⁾	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Sectoral Index ⁽⁶⁾	NA	NA	NA	NA	NA	NA

* Being index of BSE, the designated stock exchange

(1) 30th calendar day shall be taken as listing date plus 29 calendar days.

(2) 90th calendar day shall be taken as listing date plus 89 calendar days.

(3) High and Low based on intra day prices

(4) Pricing data not disclosed as the relevant period/ fiscal year has not completed

(5) In case of any reporting day falling on a holiday, next trading day prices/values have been disclosed.

(6) Comparable Sectoral index is not available

13 Basis for Issue Price

Accounting ratio	As disclosed in offer document*	At the end of 1st FY (March 31, 2024)	At the end of 2nd FY (March 31, 2025)**	At the end of 3rd FY (March 31, 2026)**
EPS (Basic)	Company Consolidated	-3.43	10.81	Not available
	Peer Group			
	MedPlus Health Services Limited (basic/diluted)	4.17/4.17	5.48	Not available
	Industry Avg	NA	NA	NA
P/E	Company Consolidated	NA	92.80	Not available
	Peer Group			
	MedPlus Health Services Limited (basic/diluted)	177.21	126.78	Not available
	Industry Avg	NA	NA	NA
RoNW	Company Consolidated	-1.86%	2.43%	Not available
	Peer Group	NA	NA	NA
	MedPlus Health Services Limited (basic/diluted)	3.36%	4.16%	Not available
	Industry Avg	NA	NA	NA
NAV per share	Company Consolidated	174.21	376.62	Not available
	Peer Group	NA	NA	NA
	MedPlus Health Services Limited (basic/diluted)	124.93%	132.00	Not available
	Industry Avg	NA	NA	NA

Notes

* Sourced from Prospectus dated February 13, 2024

**Not available as the relevant fiscal years have not been completed / information not disclosed

14 Any other material information

For further updates and information, please refer to the website of the Stock Exchanges i.e. www.bseindia.com and / or www.nseindia.com